Commonly Reported Side Effects Mild nausea or lightheadedness (typically early in the cycle) Redness or irritation at injection site Temporary headache or fatigue Tingling or nerve sensitivity in the treated area (rare) These effects are usually transient and dose-dependent
doi: 10.3389/fmed.2022.875430 Summary Keywords glucagon-like peptide-1 receptor agonist (GLP-1RA), incretin based therapy, glucose-depent insulinotropic peptide (GIP), dual agonists, tirzepatide, type 2 diabetes Citation Gallwitz B (2022) Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Methods and patients The study was conducted on 75 patients with mild-to-moderate COVID-19 hospitalized in Shahid Beheshti Hospital-Hamadan, IRAN
When not training, take 2 capsules in the morning before breakfast
Mitochondrial malfunction and atrophy of astrocytes in the aged human cerebral cortex
I use Rho Nutrition because their liposomal technology is designed to support absorption